ADPRS Knockout cell line (HCC1806)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ADPRS (ADP-ribosylserine hydrolase) encodes an enzyme belonging to the ADP-ribosylglycohydrolase family that removes ADP-ribose modifications from ADP-ribosylated proteins. By reversing protein ADP-ribosylation, ADPRS contributes to the regulation of protein modification and cellular signaling. The enzyme is localized in mitochondria as well as the nucleus and cytoplasm, supporting roles in multiple cellular compartments.

The HCC1806 breast cancer cell line was initiated on July 31, 1995, and required a periods of 10 months to be fully established. Characterized as a reliable human in vitro model, HCC1806 is extensively applied in oncology research to investigate the underlying mechanisms of breast cancer progression, tumor cell proliferation, and to evaluate the efficacy of novel therapeutic compounds during drug screening.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.